Home Amines 105601-04-5
105601-04-5,MFCD08272688
Catalog No.:AA00HAL7

105601-04-5 | 3-[1-(Dimethylamino)ethyl]phenol

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1g
98%(GC)
in stock  
$24.00   $17.00
- +
5g
97%
in stock  
$37.00   $26.00
- +
25g
97%
in stock  
$79.00   $55.00
- +
100g
97%
in stock  
$211.00   $148.00
- +
500g
97%
in stock  
$710.00   $497.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00HAL7
Chemical Name:
3-[1-(Dimethylamino)ethyl]phenol
CAS Number:
105601-04-5
Molecular Formula:
C10H15NO
Molecular Weight:
165.2322
MDL Number:
MFCD08272688
SMILES:
CN(C(c1cccc(c1)O)C)C
Properties
Computed Properties
 
Complexity:
136  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
12  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
2  
Undefined Atom Stereocenter Count:
1  
XLogP3:
1.8  

Literature

Title: Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

Journal: Journal of pharmaceutical and biomedical analysis 20120501

Title: Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.

Journal: Journal of Alzheimer's disease : JAD 20120101

Title: Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.

Journal: Drug testing and analysis 20100501

Title: Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

Journal: Electrophoresis 20090201

Title: Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

Journal: Journal of clinical pharmacology 20080201

Title: Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

Journal: Clinical pharmacology and therapeutics 20080101

Title: Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.

Journal: Clinical drug investigation 20080101

Title: [Synthesis of S-(+)-rivastigmine hydrogentartrate].

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070201

Title: A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

Journal: Rapid communications in mass spectrometry : RCM 20060101

Title: A stability indicating LC method for rivastigmine hydrogen tartrate.

Journal: Journal of pharmaceutical and biomedical analysis 20050207

Title: A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.

Journal: Biomedical chromatography : BMC 20040401

Title: Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

Journal: Biochemistry 20020319

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:105601-04-5 Molecular Formula|105601-04-5 MDL|105601-04-5 SMILES|105601-04-5 3-[1-(Dimethylamino)ethyl]phenol